Conjugation pathways in liver disease.

No abstract is available for this paper.

• Publication year

  1990

• Venue

  British Journal of Clinical Pharmacology

• Publication date

  1990-09-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1111/J.1365-2125.1990.TB03794.XPMID 2223421PMCID PMC1368146
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• 7-Ethoxyresorufin deethylase (EROD) in human liver —The effect of alcoholic liver disease

  2006cited by this paper
• Cytosolic epoxide hydrolase in humans: development and tissue distribution

  2004cited by this paper
• Glutathione S-transferase in humans: development and tissue distribution

  2004cited by this paper
• Influence of liver disease and environmental factors on hepatic monooxygenase activity in vitro

  2004cited by this paper
• The effect of alcoholic cirrhosis on the two kinetic components (high and low affinity) of the microsomal 0-deethylation of 7-ethoxycoumarin in human liver

  2004cited by this paper
• Drug metabolism in liver disease.

  1989cited by this paper
• Hepatic drug clearance in chronic liver disease: Can we expect to find a universal, quantitative marker of hepatic function?

  1989cited by this paper
• Tissue distribution of drug-metabolizing enzymes in humans.

  1988cited by this paper
• Guide to Drug Dosage in Hepatic Disease

  1988cited by this paper
• Sulfotransferase in humans: development and tissue distribution.

  1988cited by this paper
• Sulphation and glucuronidation of ethinyloestradiol in human liver in vitro.

  1988cited by this paper
• Mouse liver thiol methyltransferase. Assay conditions, biochemical properties, and strain variation.

  1986cited by this paper
• Acetyltransferase in humans: development and tissue distribution.

  1986cited by this paper
• Clinical Pharmacokinetics of Oral Contraceptive Steroids

  1983cited by this paper
• The effect of alcoholic cirrhosis on the activities of microsomal aldrin epoxidase, 7-ethoxycoumarin O-de-ethylase and epoxide hydrolase, and on the concentrations of reduced glutathione in human liver.

  1983cited by this paper
• The clinical pharmacology of oral contraceptive steroids.

  1982cited by this paper
• The third S.K. & F. Prize lecture, University of London, December 1981. The clinical pharmacology of oral contraceptive steroids.

  1982cited by this paper
• Monooxygenase activity of human liver in microsomal fractions of needle biopsy specimens.

  1980cited by this paper
• Hepatic Disease and Drug Pharmacokinetics

  1980cited by this paper
• Metabolism of estrogens--natural and synthetic.

  1979cited by this paper
• Drug metabolism in liver disease: Activity of hepatic microsomal metabolizing enzymes

  1979cited by this paper
• Determination of microsomal UDP-glucuronyltransferase in needle-biopsy specimens of human liver

  1978cited by this paper
• Hepatocellular carcinoma in Great Britain: influence of age, sex, HBsAg status, and aetiology of underlying cirrhosis.

  1978cited by this paper
• Drug metabolism in liver disease

  1975cited by this paper
• A Multiple Comparison Procedure for Comparing Several Treatments with a Control

  1955cited by this paper
• Protein measurement with the Folin phenol reagent.

  1951cited by this paper

• Effect of Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of SHR4640, a Selective Human Urate Transporter 1 Inhibitor

  2024cites this paper
• Acute on Chronic Liver Failure

  2019cites this paper
• Interaction of Oatp1b2 Expression and Nonalcoholic Steatohepatitis on Pravastatin Plasma Clearance.

  2019cites this paper
• Pharmacokinetics and Safety of a Single Oral Dose of Peficitinib (ASP015K) in Japanese Subjects With Normal and Impaired Hepatic Function

  2019cites this paper
• Dotinurad: a clinical pharmacokinetic study of a novel, selective urate reabsorption inhibitor in subjects with hepatic impairment

  2019cites this paper
• Clinical Pharmacology of Delafloxacin in Patients With Hepatic Impairment

  2016cites this paper
• Psychopharmacology in Medically Ill Patients

  2015cites this paper
• Sequencing and molecular characterization of variations in the glycine N-acyltransferase gene

  2014cites this paper
• Effects of liver diseases on drug-metabolizing enzymes: implications for drug fate alterations and nano-therapeutic openings.

  2014cites this paper
• Relevance of liver failure for anti-infective agents: from pharmacokinetic alterations to dosage adjustments

  2014cites this paper
• Pharmacokinetic of Antiepileptic Drugs in Patients with Hepatic or Renal Impairment

  2013cites this paper
• Inauguraldissertation zur Erlangung der Würde eines Doktors der Philosophie vorgelegt der

  2012cites this paper
• Effects of Disease on Drug Disposition

  2010cites this paper
• Hepatobiliary Excretion of Silibinin in Normal and Liver Cirrhotic Rats

  2008cites this paper
• An overview of psychiatric issues in liver disease for the consultation-liaison psychiatrist.

  2006cites this paper
• Farmacos de acción lenta (Sysadoa) en el tratamiento de la osteoartrosis

  2006cites this paper
• Dose adaptation of drugs in patients with liver disease

  2004influential citation
• The effect of liver cirrhosis on the regulation and expression of drug metabolizing enzymes.

  2004cites this paper
• Dose Adaptation of Drugs in Patients with Liver Disease

  2004cites this paper
• Influence of cirrhosis on lamotrigine pharmacokinetics.

  2001cites this paper
• Single‐Dose Pharmacokinetics of Repaglinide in Subjects with Chronic Liver Disease

  2000cites this paper
• Pharmacokinetics of Opioids in Liver Disease

  1999cites this paper
• Drug Acetylation in Liver Disease

  1998cites this paper
• Clinical Pharmacokinetics of Diacerein

  1998cites this paper
• Pharmacokinetics of Dolasetron after Oral and Intravenous Administration of Dolasetron Mesylate in Healthy Volunteers and Patients with Hepatic Dysfunction

  1997cites this paper
• The effects of diet, aging and disease-states on presystemic elimination and oral drug bioavailability in humans.

  1997cites this paper
• Drug Administration in Chronic Liver Disease

  1997cites this paper
• Zidovudine glucuronidation in human liver: interindividual variability.

  1996cites this paper
• Idiosyncratic liver toxicity of nonsteroidal antiinflammatory drugs: molecular mechanisms and pathology.

  1995cites this paper
• Glutathione conjugation with 1-chloro-2,4-dinitrobenzene (CDNB): interindividual variability in human liver, lung, kidney and intestine.

  1995cites this paper
• Psychopharmacologic issues in organ transplantation. Part 2: Psychopharmacologic medications.

  1993cites this paper
• Psychopharmacologic issues in organ transplantation. Part I: Pharmacokinetics in organ failure and psychiatric aspects of immunosuppressants and anti-infectious agents.

  1993cites this paper
• Clinical Pharmacokinetics of Newer Antibacterial Agents in Liver Disease

  1993cites this paper
• Antipyrine Kinetics in Patients with Primary Biliary Cirrhosis

  1993cites this paper
• Pharmacokinetics of diacerein in patients with liver cirrhosis

  1993cites this paper
• Interindividual variability in the N-sulphation of desipramine in human liver and platelets.

  1992cites this paper
• Glucuronidation and its role in regulation of biological activity of drugs.

  1992cites this paper
• Clinical Pharmacokinetics in Patients with Liver Disease

  1991cites this paper